Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

@article{Omuro2015MethotrexateAT,
  title={Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.},
  author={A Omuro and Olivier L. Chinot and Luc Taillandier and Herv{\'e} Ghesqui{\`e}res and Carole Soussain and V Delwail and Thierry Lamy and R{\'e}my Gressin and Sylvain Choquet and Pierre Soubeyran and Aymeri Huchet and Alexandra Benouaich-Amiel and Sophie Lebouvier-Sadot and Emmanuel Gyan and Val{\'e}rie Touitou and Maryline Barri{\'e} and Monica Sierra del Rio and Alberto Gonz{\'a}lez-Aguilar and Caroline Houillier and Daniel Delgadillo and Lucette Lacomblez and Marie Laure Tanguy and Kh{\^e} Hoang-Xuan},
  journal={The Lancet. Haematology},
  year={2015},
  volume={2 6},
  pages={e251-9}
}
BACKGROUND No standard chemotherapy regimen exists for primary CNS lymphoma, reflecting an absence of randomised studies. We prospectively tested two promising methotrexate-based regimens, one more intensive and a milder regimen, for primary CNS lymphoma in the elderly population, who account for most patients. METHODS In this open-label, randomised phase 2 trial, done in 13 French institutions, we enrolled immunocompetent patients who had neuroimaging and histologically confirmed newly… CONTINUE READING
11 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…